Effects of complexing treatment administered with the onset of methyl mercury neurotoxic signs.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002614:Chelating Agents / Q000627:therapeutic use*; D004112:Dimercaprol / Q000627:therapeutic use; D005260:Female; D005966:Glucuronidase / Q000378:metabolism; D008628:Mercury / Q000378:metabolism; D008767:Methylmercury Compounds / Q000378:metabolism / Q000506:poisoning*; D009422:Nervous System Diseases / Q000139:chemically induced / Q000188:drug therapy*; D010396:Penicillamine / Q000627:therapeutic use; D051381:Rats; D013997:Time Factors
D002614:Chelating Agents; D008767:Methylmercury Compounds; D004112:Dimercaprol; D005966:Glucuronidase; D008628:Mercury; D010396:Penicillamine